{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:01:28Z","timestamp":1771862488419,"version":"3.50.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00228-025-03957-w","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:11:28Z","timestamp":1769829088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of treatments for atopic dermatitis: a model based meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"82","author":[{"given":"Lingxiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianhui","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"5","key":"3957_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A et al (2018) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 32(5):657\u2013682. https:\/\/doi.org\/10.1111\/jdv.14891","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10247","key":"3957_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31825-0","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S (2020) Atopic dermatitis. Lancet 396(10247):345\u2013360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31825-0","journal-title":"Lancet"},{"issue":"8 Suppl","key":"3957_CR3","first-page":"S115","volume":"23","author":"C Avena-Woods","year":"2017","unstructured":"Avena-Woods C (2017) Overview of atopic dermatitis. Am J Manag Care 23(8 Suppl):S115\u2013S123","journal-title":"Am J Manag Care"},{"issue":"4","key":"3957_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s13555-022-00700-6","volume":"12","author":"T Luger","year":"2022","unstructured":"Luger T, Romero WA, Gruben D, Smith TW, Cha A, Neary MP (2022) Clinical and humanistic burden of atopic dermatitis in europe: analyses of the National health and wellness survey. Dermatol Ther (Heidelb) 12(4):949\u2013969. https:\/\/doi.org\/10.1007\/s13555-022-00700-6Epub 2022 Mar 28","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"3957_CR5","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S, Atopic Dermatitis (2021) N Engl J Med 384(12):1136\u20131143. https:\/\/doi.org\/10.1056\/NEJMra2023911","journal-title":"N Engl J Med"},{"issue":"11","key":"3957_CR6","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/jdv.18429","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S et al (2022) European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol 36(11):1904\u20131926. https:\/\/doi.org\/10.1111\/jdv.18429","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3957_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM et al (2023) Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol 89(1):e1\u2013e20. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.029","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3957_CR8","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM et al (2024) Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 90(2):e43\u2013e56. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.102","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3957_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.alit.2022.06.009","volume":"71","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ohya Y, Furuta J, Arakawa H, Ichiyama S, Katsunuma T et al (2022) Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int 71(4):448\u2013458. https:\/\/doi.org\/10.1016\/j.alit.2022.06.009","journal-title":"Allergol Int"},{"issue":"9","key":"3957_CR10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S et al (2021) Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 157(9):1047\u20131055. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023","journal-title":"JAMA Dermatol"},{"issue":"3","key":"3957_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184(3):437\u2013449. https:\/\/doi.org\/10.1111\/bjd.19574Epub 2020 Dec 30","journal-title":"Br J Dermatol"},{"issue":"2","key":"3957_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, Graham NM, Bieber T, Rocklin R et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371(2):130\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa1314768","journal-title":"N Engl J Med"},{"issue":"24","key":"3957_CR13","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375(24):2335\u20132348. https:\/\/doi.org\/10.1056\/NEJMoa1610020Epub 2016 Sep 30","journal-title":"N Engl J Med"},{"issue":"10246","key":"3957_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M et al (2020) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 396(10246):255\u2013266. https:\/\/doi.org\/10.1016\/S0140-6736(20)30732-7","journal-title":"Lancet"},{"issue":"10290","key":"3957_CR15","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A et al (2021) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 397(10290):2151\u20132168. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2","journal-title":"Lancet"},{"issue":"8","key":"3957_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C et al (2020) Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156(8):863\u2013873. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406","journal-title":"JAMA Dermatol"},{"issue":"1","key":"3957_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ et al (2020) Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 156(1):44\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336","journal-title":"JAMA Dermatol"},{"issue":"2","key":"3957_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","volume":"87","author":"VY Shi","year":"2022","unstructured":"Shi VY, Bhutani T, Fonacier L, Deleuran M, Shumack S, Valdez H et al (2022) Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol 87(2):351\u2013358. https:\/\/doi.org\/10.1016\/j.jaad.2022.04.009","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"3957_CR19","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, Irvine AD, Stein Gold L, Blauvelt A et al (2023) Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 388(12):1080\u20131091. https:\/\/doi.org\/10.1056\/NEJMoa2206714. (Epub 2023 Mar 15)","journal-title":"N Engl J Med"},{"issue":"1","key":"3957_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J et al (2022) Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol 86(1):104\u2013112. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.075","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3957_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","volume":"145","author":"BS Kim","year":"2020","unstructured":"Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME (2020) Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol 145(2):572\u2013582. https:\/\/doi.org\/10.1016\/j.jaci.2019.08.042","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3957_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, Hong HC, Papp KA, Reich K et al (2020) Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 145(3):877\u2013884. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.025","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"3957_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J et al (2020) Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol 156(4):411\u2013420. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0079","journal-title":"JAMA Dermatol"},{"issue":"2","key":"3957_CR24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","volume":"144","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H et al (2019) GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol 144(2):482-493.e7. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.053","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3957_CR25","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jaad.2020.05.135","volume":"84","author":"AS Paller","year":"2021","unstructured":"Paller AS, Stein Gold L, Soung J, Tallman AM, Rubenstein DS, Gooderham M (2021) Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol 84(3):632\u2013638. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.135","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3957_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaad.2021.10.027","volume":"86","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ito K, Yokota D, Tsubouchi H (2022) Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 86(3):607\u2013614. https:\/\/doi.org\/10.1016\/j.jaad.2021.10.027","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3957_CR27","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjd.20690","volume":"186","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Wu L, Lu Q, Gao X, Zhu X, Yao X et al (2022) The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 186(4):633\u2013641. https:\/\/doi.org\/10.1111\/bjd.20690","journal-title":"Br J Dermatol"},{"issue":"4","key":"3957_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","volume":"82","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T (2020) Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol 82(4):823\u2013831. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3957_CR29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","volume":"85","author":"H Nakagawa","year":"2021","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kabashima K, Oda M et al (2021) Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol 85(4):854\u2013862. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.014","journal-title":"J Am Acad Dermatol"},{"issue":"10372","key":"3957_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","volume":"401","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T et al (2023) An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet 401(10372):204\u2013214. https:\/\/doi.org\/10.1016\/S0140-6736(22)02037-2","journal-title":"Lancet"},{"issue":"1","key":"3957_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjd.20655","volume":"186","author":"H Saeki","year":"2022","unstructured":"Saeki H, Baba N, Ito K, Yokota D, Tsubouchi H (2022) Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial. Br J Dermatol 186(1):40\u201349. https:\/\/doi.org\/10.1111\/bjd.20655","journal-title":"Br J Dermatol"},{"issue":"1","key":"3957_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Forman S, Silverberg JI, Zirwas M, Maverakis E, Han G et al (2021) Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol 85(1):62\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.028","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3957_CR33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40257-021-00627-2","volume":"22","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhang L, Ding Y, Tao X, Ji C, Dong X et al (2021) Efficacy and safety of SHR0302, a highly selective Janus kinase 1 inhibitor, in patients with moderate to severe atopic dermatitis: A phase II randomized clinical trial. Am J Clin Dermatol 22(6):877\u2013889. https:\/\/doi.org\/10.1007\/s40257-021-00627-2. (Epub 2021 Aug 9)","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"3957_CR34","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C et al (2019) Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: A phase 2 randomized clinical trial. JAMA Dermatol 155(12):1371\u20131379. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2855","journal-title":"JAMA Dermatol"},{"issue":"10013","key":"3957_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","volume":"387","author":"D Tha\u00e7i","year":"2016","unstructured":"Tha\u00e7i D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K et al (2016) Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387(10013):40\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(15)00388-8","journal-title":"Lancet"},{"issue":"10","key":"3957_CR36","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1111\/cts.13363","volume":"15","author":"MA Kamal","year":"2022","unstructured":"Kamal MA, Davis JD, Kovalenko P, Srinivasan K, Simpson EL, Nakahara T et al (2022) Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis. Clin Transl Sci 15(10):2342\u20132354. https:\/\/doi.org\/10.1111\/cts.13363","journal-title":"Clin Transl Sci"},{"issue":"5","key":"3957_CR37","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","volume":"175","author":"R Bissonnette","year":"2016","unstructured":"Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L et al (2016) Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 175(5):902\u2013911. https:\/\/doi.org\/10.1111\/bjd.14871","journal-title":"Br J Dermatol"},{"issue":"9","key":"3957_CR38","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1606490","volume":"376","author":"T Ruzicka","year":"2017","unstructured":"Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A et al (2017) Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 376(9):826\u2013835. https:\/\/doi.org\/10.1056\/NEJMoa1606490","journal-title":"N Engl J Med"},{"key":"3957_CR39","doi-asserted-by":"publisher","first-page":"112477","DOI":"10.1016\/j.jep.2019.112477","volume":"250","author":"YK Lin","year":"2020","unstructured":"Lin YK, Chang SH, Yang CY, See LC, Lee BH, Shih IH (2020) Efficacy and safety of Indigo naturalis ointment in treating atopic dermatitis: A randomized clinical trial. J Ethnopharmacol 250:112477. https:\/\/doi.org\/10.1016\/j.jep.2019.112477Epub 2019 Dec 12","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"3957_CR40","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jaci.2021.09.024","volume":"149","author":"CW Park","year":"2022","unstructured":"Park CW, Kim BJ, Lee YW, Won C, Park CO, Chung BY et al (2022) Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: Phase 3, randomized, vehicle-controlled study (CAPTAIN-AD). J Allergy Clin Immunol 149(4):1340-1347.e4. https:\/\/doi.org\/10.1016\/j.jaci.2021.09.024","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"3957_CR41","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/jdv.18914","volume":"37","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Bissonnette R, Kircik L, Murrell DF, Selfridge A, Liu K et al (2023) Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE). J Eur Acad Dermatol Venereol 37(7):1366\u20131374. https:\/\/doi.org\/10.1111\/jdv.18914","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"3957_CR42","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jaci.2014.08.002","volume":"134","author":"CA Camargo","year":"2014","unstructured":"Camargo CA, Ganmaa D, Sidbury R, Erdenedelger Kh, Radnaakhand N, Khandsuren B (2014) Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. J Allergy Clin Immunol 134(4):831-835.e1. https:\/\/doi.org\/10.1016\/j.jaci.2014.08.002","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3957_CR43","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.jaci.2018.07.047","volume":"143","author":"T Werfel","year":"2019","unstructured":"Werfel T, Layton G, Yeadon M, Whitlock L, Osterloh I, Jimenez P et al (2019) Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis. J Allergy Clin Immunol 143(5):1830-1837.e4. https:\/\/doi.org\/10.1016\/j.jaci.2018.07.047","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3957_CR44","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bjd.21826","volume":"187","author":"MN Landis","year":"2022","unstructured":"Landis MN, Arya M, Smith S, Draelos Z, Usdan L, Tarabar S et al (2022) Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study. Br J Dermatol 187(6):878\u2013887. https:\/\/doi.org\/10.1111\/bjd.21826","journal-title":"Br J Dermatol"},{"issue":"5","key":"3957_CR45","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1542\/peds.2008-2217","volume":"123","author":"JT Huang","year":"2009","unstructured":"Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS (2009) Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 123(5):e808\u2013e814. https:\/\/doi.org\/10.1542\/peds.2008-2217","journal-title":"Pediatrics"},{"issue":"4","key":"3957_CR46","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/pde.12867","volume":"33","author":"L Schneider","year":"2016","unstructured":"Schneider L, Hanifin J, Boguniewicz M, Eichenfield LF, Spergel JM, Dakovic R et al (2016) Study of the atopic march: development of atopic comorbidities. Pediatr Dermatol 33(4):388\u201398. https:\/\/doi.org\/10.1111\/pde.12867","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"3957_CR47","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3109\/09546634.2013.800181","volume":"24","author":"H Ucak","year":"2013","unstructured":"Ucak H, Demir B, Cicek D, Dertlioglu SB, Akkurt ZM, Ucmak D et al (2013) Efficacy of topical tacrolimus for the treatment of persistent pruritus ani in patients with atopic dermatitis. J Dermatolog Treat 24(6):454\u20137. https:\/\/doi.org\/10.3109\/09546634.2013.800181","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"3957_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","volume":"80","author":"J Peppers","year":"2019","unstructured":"Peppers J, Paller AS, Maeda-Chubachi T, Wu S, Robbins K, Gallagher K et al (2019) A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol 80(1):89-98.e3. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.047","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"3957_CR49","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1346-8138.16792","volume":"50","author":"L Ma","year":"2023","unstructured":"Ma L, Zhang L, Kobayashi M, Tao X, Qian Q, Cheng H et al (2023) Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged\u2009\u2265\u20092 years with mild-to-moderate atopic dermatitis. J Dermatol 50(7):847\u2013855. https:\/\/doi.org\/10.1111\/1346-8138.16792","journal-title":"J Dermatol"},{"issue":"1","key":"3957_CR50","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/00015550510044163","volume":"86","author":"TY Tzung","year":"2006","unstructured":"Tzung TY, Lin CB, Chen YH, Yang CY (2006) Pimecrolimus and narrowband UVB as monotherapy or combination therapy in children and adolescents with atopic dermatitis. Acta Derm Venereol 86(1):34\u201338. https:\/\/doi.org\/10.1080\/00015550510044163","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"3957_CR51","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1046\/j.1365-2133.2001.04134.x","volume":"144","author":"T Luger","year":"2001","unstructured":"Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A et al (2001) SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 144(4):788\u201394. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04134.x","journal-title":"Br J Dermatol"},{"issue":"6","key":"3957_CR52","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","volume":"150","author":"M Maurer","year":"2022","unstructured":"Maurer M, Cheung DS, Theess W, Yang X, Dolton M, Guttman A et al (2022) Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis. J Allergy Clin Immunol 150(6):1517\u20131524. https:\/\/doi.org\/10.1016\/j.jaci.2022.08.015","journal-title":"J Allergy Clin Immunol"},{"issue":"1S","key":"3957_CR53","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1097\/DER.0000000000000725","volume":"32","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Wollenberg A, Bissonnette R, Silverberg JI, Papacharalambous J, Zhu L et al (2021) Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib. Dermatitis 32(1S):S53\u2013S61. https:\/\/doi.org\/10.1097\/DER.0000000000000725","journal-title":"Dermatitis"},{"issue":"6","key":"3957_CR54","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/1346-8138.14322","volume":"45","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Nemoto O, Yamada H, Nagata T, Ninomiya N (2018) Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol 45(6):701\u2013709. https:\/\/doi.org\/10.1111\/1346-8138.14322","journal-title":"J Dermatol"},{"issue":"2","key":"3957_CR55","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jaad.2016.04.001","volume":"75","author":"JM Hanifin","year":"2016","unstructured":"Hanifin JM, Ellis CN, Frieden IJ, F\u00f6lster-Holst R, Stein Gold LF, Secci A et al (2016) OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 75(2):297\u2013305. https:\/\/doi.org\/10.1016\/j.jaad.2016.04.001","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3957_CR56","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","volume":"139","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, Imafuku S, Poulin Y, Ungar B, Zhou L, Malik K et al (2019) A phase 2 randomized trial of apremilast in patients with atopic dermatitis. J Invest Dermatol 139(5):1063\u20131072. https:\/\/doi.org\/10.1016\/j.jid.2018.10.043","journal-title":"J Invest Dermatol"},{"issue":"2","key":"3957_CR57","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/bjd.15493","volume":"177","author":"H Saeki","year":"2017","unstructured":"Saeki H, Kabashima K, Tokura Y, Murata Y, Shiraishi A, Tamamura R et al (2017) Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol 177(2):419\u2013427. https:\/\/doi.org\/10.1111\/bjd.15493Epub 2017 Jun 27","journal-title":"Br J Dermatol"},{"issue":"2","key":"3957_CR58","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1067\/mpd.2003.65","volume":"142","author":"VC Ho","year":"2003","unstructured":"Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R et al (2003) Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 142(2):155\u201362. https:\/\/doi.org\/10.1067\/mpd.2003.65","journal-title":"J Pediatr"},{"issue":"1","key":"3957_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medicina59010015","volume":"59","author":"A Bogacz-Piaseczy\u0144ska","year":"2022","unstructured":"Bogacz-Piaseczy\u0144ska A, Bo\u017cek A (2022) The effectiveness of allergen immunotherapy in adult patients with atopic dermatitis allergic to house dust mites. Med (Kaunas) 59(1):15. https:\/\/doi.org\/10.3390\/medicina59010015","journal-title":"Med (Kaunas)"},{"issue":"4","key":"3957_CR60","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bjd.17932","volume":"181","author":"R Bissonnette","year":"2019","unstructured":"Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J et al (2019) The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol 181(4):733\u2013742. https:\/\/doi.org\/10.1111\/bjd.17932","journal-title":"Br J Dermatol"},{"key":"3957_CR61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctim.2018.07.007","volume":"40","author":"JH Ahn","year":"2018","unstructured":"Ahn JH, Yun Y, Kim MH, Ko SG, Kim KS, Choi I (2018) Exploring the efficacy and safety of topical Jaungo application in patients with atopic dermatitis: a pilot randomized, double-blind, placebo-controlled study. Complement Ther Med 40:22\u201328. https:\/\/doi.org\/10.1016\/j.ctim.2018.07.007","journal-title":"Complement Ther Med"},{"issue":"5","key":"3957_CR62","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/bjd.17455","volume":"180","author":"YW Lee","year":"2019","unstructured":"Lee YW, Won CH, Jung K, Nam HJ, Choi G, Park YH et al (2019) Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial. Br J Dermatol 180(5):1030\u20131038. https:\/\/doi.org\/10.1111\/bjd.17455Epub 2019 Jan 8","journal-title":"Br J Dermatol"},{"issue":"2","key":"3957_CR63","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1398-9995.2006.01269.x","volume":"62","author":"T Bieber","year":"2007","unstructured":"Bieber T, Vick K, F\u00f6lster-Holst R, Belloni-Fortina A, St\u00e4dtler G, Worm M et al (2007) Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 62(2):184\u20139. https:\/\/doi.org\/10.1111\/j.1398-9995.2006.01269.x","journal-title":"Allergy"},{"issue":"6","key":"3957_CR64","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","volume":"144","author":"H Nakagawa","year":"2019","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Oda M, Kabashima K et al (2019) Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol 144(6):1575\u20131583. https:\/\/doi.org\/10.1016\/j.jaci.2019.08.004","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3957_CR65","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1542\/peds.2004-2638","volume":"116","author":"LA Schachner","year":"2005","unstructured":"Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S et al (2005) Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. Pediatrics 116(3):e334\u2013e342. https:\/\/doi.org\/10.1542\/peds.2004-2638","journal-title":"Pediatrics"},{"issue":"1","key":"3957_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/1346-8138.15137","volume":"47","author":"H Saeki","year":"2020","unstructured":"Saeki H, Baba N, Oshiden K, Abe Y, Tsubouchi H (2020) Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA-15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2\u201314 years with atopic dermatitis. J Dermatol 47(1):17\u201324. https:\/\/doi.org\/10.1111\/1346-8138.15137","journal-title":"J Dermatol"},{"issue":"4","key":"3957_CR67","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1159\/000080855","volume":"209","author":"K Breuer","year":"2004","unstructured":"Breuer K, Braeutigam M, Kapp A, Werfel T (2004) Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology 209(4):314\u2013320. https:\/\/doi.org\/10.1159\/000080855","journal-title":"Dermatology"},{"issue":"1","key":"3957_CR68","doi-asserted-by":"publisher","first-page":"109","DOI":"10.21873\/invivo.11446","volume":"33","author":"K Nakai","year":"2019","unstructured":"Nakai K, Kubota Y, Soma GI, Kohchi C (2019) The effect of lipopolysaccharide-containing moisturizing cream on skin care in patients with mild atopic dermatitis. In Vivo 33(1):109\u2013114. https:\/\/doi.org\/10.21873\/invivo.11446","journal-title":"In Vivo"},{"issue":"4","key":"3957_CR69","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/j.1365-2133.2006.07410.x","volume":"155","author":"JQ Gong","year":"2006","unstructured":"Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG et al (2006) Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol 155(4):680\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07410.x","journal-title":"Br J Dermatol"},{"issue":"6","key":"3957_CR70","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC et al (2023) Efficacy and safety of Tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol 159(6):596\u2013605. https:\/\/doi.org\/10.1001\/jamadermatol.2023.0627","journal-title":"JAMA Dermatol"},{"issue":"4","key":"3957_CR71","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1067\/mjd.2002.122187","volume":"46","author":"LF Eichenfield","year":"2002","unstructured":"Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K et al (2002) Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 46(4):495\u2013504. https:\/\/doi.org\/10.1067\/mjd.2002.122187","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"3957_CR72","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/1346-8138.12534","volume":"41","author":"M Furue","year":"2014","unstructured":"Furue M, Kitahara Y, Akama H, Hojo S, Hayashi N, Nakagawa H (2014) Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol 41(7):577\u201385. https:\/\/doi.org\/10.1111\/1346-8138.12534","journal-title":"J Dermatol"},{"issue":"1","key":"3957_CR73","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1365-2133.2012.11177.x","volume":"168","author":"SH Wu","year":"2013","unstructured":"Wu SH, Chen XQ, Liu B, Wu HJ, Dong L (2013) Efficacy and safety of 15(R\/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br J Dermatol 168(1):172\u2013178. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11177.x","journal-title":"Br J Dermatol"},{"issue":"1 Pt 1","key":"3957_CR74","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1542\/peds.110.1.e2","volume":"110","author":"U Wahn","year":"2002","unstructured":"Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A et al (2002) Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110(1 Pt 1):e2. https:\/\/doi.org\/10.1542\/peds.110.1.e2","journal-title":"Pediatrics"},{"issue":"6","key":"3957_CR75","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/j.1365-2133.2005.06674.x","volume":"152","author":"K Wolff","year":"2005","unstructured":"Wolff K, Fleming C, Hanifin J, Papp K, Reitamo S, Rustin M et al (2005) Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 152(6):1296\u20131303. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06674.x","journal-title":"Br J Dermatol"},{"issue":"6","key":"3957_CR76","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1399-3038.2005.00306.x","volume":"16","author":"D Staab","year":"2005","unstructured":"Staab D, Kaufmann R, Br\u00e4utigam M, Wahn U (2005) Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents\u2019 quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol 16(6):527\u201333. https:\/\/doi.org\/10.1111\/j.1399-3038.2005.00306.x","journal-title":"Pediatr Allergy Immunol"},{"issue":"5","key":"3957_CR77","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jaci.2004.08.015","volume":"114","author":"R Kaufmann","year":"2004","unstructured":"Kaufmann R, F\u00f6lster-Holst R, H\u00f6ger P, Tha\u00e7i D, L\u00f6ffler H, Staab D et al (2004) Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 114(5):1183\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2004.08.015","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3957_CR78","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/bjd.15905","volume":"178","author":"A Tsianakas","year":"2018","unstructured":"Tsianakas A, Luger TA, Radin A (2018) Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. Br J Dermatol 178(2):406\u2013414. https:\/\/doi.org\/10.1111\/bjd.15905","journal-title":"Br J Dermatol"},{"issue":"7","key":"3957_CR79","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1399-3038.2007.00706.x","volume":"19","author":"J Szczepanowska","year":"2008","unstructured":"Szczepanowska J, Reich A, Szepietowski JC (2008) Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol 19(7):614\u20138. https:\/\/doi.org\/10.1111\/j.1399-3038.2007.00706.x","journal-title":"Pediatr Allergy Immunol"},{"issue":"2","key":"3957_CR80","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/1346-8138.12726","volume":"42","author":"Y Murata","year":"2015","unstructured":"Murata Y, Song M, Kikuchi H, Hisamichi K, Xu XL, Greenspan A et al (2015) Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol 42(2):129\u201339. https:\/\/doi.org\/10.1111\/1346-8138.12726","journal-title":"J Dermatol"},{"issue":"2","key":"3957_CR81","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2133.2009.09145.x","volume":"161","author":"DY Leung","year":"2009","unstructured":"Leung DY, Hanifin JM, Pariser DM, Barber KA, Langley RG, Schlievert PM et al (2009) Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. Br J Dermatol 161(2):435\u201343. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09145.x","journal-title":"Br J Dermatol"},{"issue":"2","key":"3957_CR82","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2340\/00015555-0803","volume":"90","author":"J Mandelin","year":"2010","unstructured":"Mandelin J, Remitz A, Virtanen H, Reitamo S (2010) One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol 90(2):170\u2013174. https:\/\/doi.org\/10.2340\/00015555-0803","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"3957_CR83","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jdv.18727","volume":"37","author":"R Bissonnette","year":"2023","unstructured":"Bissonnette R, Abramovits W, Saint-Cyr Proulx \u00c9, Lee P, Guttman-Yassky E, Zovko E et al (2023) Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study. J Eur Acad Dermatol Venereol 37(3):549\u2013557. https:\/\/doi.org\/10.1111\/jdv.18727","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"3957_CR84","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jaad.2004.12.038","volume":"52","author":"AS Paller","year":"2005","unstructured":"Paller AS, Lebwohl M, Fleischer AB Jr, Antaya R, Langley RG, Kirsner RS et al (2005) Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 52(5):810\u201322. https:\/\/doi.org\/10.1016\/j.jaad.2004.12.038","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3957_CR85","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1365-2133.2005.06592.x","volume":"152","author":"S Reitamo","year":"2005","unstructured":"Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, F\u00f6lster-Holst R et al (2005) A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 152(6):1282\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06592.x","journal-title":"Br J Dermatol"},{"issue":"2","key":"3957_CR86","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R et al (2020) Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 183(2):242\u2013255. https:\/\/doi.org\/10.1111\/bjd.18898Epub 2020 Mar 5","journal-title":"Br J Dermatol"},{"key":"3957_CR87","unstructured":"U.S. Food and Drug Administration (FDA). Medical Review: NDA 207695. Anacor Pharmaceuticals Inc.; November 5 (2015) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/207695Orig1s000MedR.pdf"},{"key":"3957_CR88","unstructured":"U.S. Food and Drug Administration (FDA) (2018) Multi-Disciplinary review and evaluation: NDA 215309. Incyte corporation; October 12, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/215309Orig1s000MultidisciplineR.pdf"},{"issue":"6","key":"3957_CR89","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","volume":"152","author":"DK Chu","year":"2023","unstructured":"Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nu\u00f1ez JJ, Gomez-Escobar L et al (2023) Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol 152(6):1493\u20131519. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.030","journal-title":"J Allergy Clin Immunol"},{"key":"3957_CR90","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M et al (2018) In vitro and in vivo characterization of the JAK1 selectivity of Upadacitinib (ABT-494). BMC Rheumatol 2:23. https:\/\/doi.org\/10.1186\/s41927-018-0031-x","journal-title":"BMC Rheumatol"},{"key":"3957_CR91","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.7573\/dic.2020-8-5","volume":"9","author":"N Nezamololama","year":"2020","unstructured":"Nezamololama N, Fieldhouse K, Metzger K, Gooderham M (2020) Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and Upadacitinib. Drugs Context 9:2020\u20132028. https:\/\/doi.org\/10.7573\/dic.2020-8-5","journal-title":"Drugs Context"},{"issue":"5","key":"3957_CR92","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","volume":"158","author":"AM Drucker","year":"2022","unstructured":"Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B et al (2022) Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol 158(5):523\u2013532. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0455","journal-title":"JAMA Dermatol"},{"issue":"6","key":"3957_CR93","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/bjd.21822","volume":"187","author":"K Capozza","year":"2022","unstructured":"Capozza K, Vastrup A, Proctor A, Roberts A, Picozza M, Manion R et al (2022) The sound of silence: where are the voices of patients in eczema guideline development? Br J Dermatol 187(6):1005\u20131006. https:\/\/doi.org\/10.1111\/bjd.21822","journal-title":"Br J Dermatol"},{"issue":"12","key":"3957_CR94","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D et al (2023) Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 388(12):1080\u20131091. https:\/\/doi.org\/10.1056\/NEJMoa2206714","journal-title":"N Engl J Med"},{"issue":"11","key":"3957_CR95","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/1346-8138.17451","volume":"51","author":"A Igarashi","year":"2024","unstructured":"Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S (2024) Tapinarof cream for the treatment of atopic dermatitis: efficacy and safety results from two Japanese phase 3 trials. J Dermatol 51(11):1404\u20131413. https:\/\/doi.org\/10.1111\/1346-8138.17451","journal-title":"J Dermatol"},{"issue":"3","key":"3957_CR96","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Eichenfield LF, Hebert AA et al (2024) Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol 91(3):457\u2013465. https:\/\/doi.org\/10.1016\/j.jaad.2024.05.023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3957_CR97","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF et al (2020) Efficacy and safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol 156(4):411\u2013420. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0079","journal-title":"JAMA Dermatol"},{"issue":"2","key":"3957_CR98","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1346-8138.17587","volume":"52","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Tsuji G, Murata R, Fukasawa S, Yamane S (2025) A phase 2, randomized, double-blind, vehicle-controlled trial of Tapinarof cream in Japanese pediatric patients with atopic dermatitis. J Dermatol 52(2):247\u2013255. https:\/\/doi.org\/10.1111\/1346-8138.17587","journal-title":"J Dermatol"},{"issue":"1","key":"3957_CR99","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","volume":"80","author":"J Peppers","year":"2019","unstructured":"Peppers J, Paller AS, Maeda-Chubachi T et al (2019) A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol 80(1):89-98.e3. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.047","journal-title":"J Am Acad Dermatol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03957-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03957-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03957-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:06:27Z","timestamp":1771859187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03957-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3957"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03957-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}